Remediation of Visual Perceptual Impairments in People With Schizophrenia

NCT03314129 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2025-09-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of a visual remediation intervention for people with schizophrenia. The intervention targets two visual functions that much research has shown are impaired in many people with the disorder, namely contrast sensitivity and perceptual organization. The first phase of the study will test the effects of interventions targeting each of these processes, as well as the effects of a combined package. A control condition of higher-level cognitive remediation is included as a fourth condition. The second phase of the study will evaluate the effectiveness of the most effective intervention from the first phase, but in a new and larger sample of individuals. Outcome measures include multiple aspects of visual functioning, as well as visual cognition and overall community functioning.

Conditions

Interventions

BEHAVIORAL

UltimEyes

A computer program developed to improve contrast sensitivity and visual acuity.

BEHAVIORAL

Contour Integration Training

A computerized program to improve contour integration (a form of perceptual organization).

BEHAVIORAL

UltimEyes + Contour Integration Training

The combination of UltimEyes and Contour Integration Training

BEHAVIORAL

MyBrainSolutions

A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.

Sponsors & Collaborators

  • New York University

    collaborator OTHER
  • Weill Medical College of Cornell University

    collaborator OTHER
  • National Institute of Mental Health (NIMH)

    collaborator NIH
  • University of Rochester

    lead OTHER

Principal Investigators

  • Steven M Silverstein, Ph.D. · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2025-03-31
Completion
2025-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03314129 on ClinicalTrials.gov